Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

19P - Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis


31 Mar 2023


Poster Display session


Nicolas Girard


Journal of Thoracic Oncology (2023) 18 (4S): S35-S88.


N. Girard1, Y. Ohe2, T.M. Kim3, L. Demirdjian4, A.B. Bourla4, A. Abdul Sultan5, P. Mahadevia6, J.M. Bauml4, J. Sabari7

Author affiliations

  • 1 Institut Curie, Paris/FR
  • 2 National Cancer Center Hospital, Tokyo/JP
  • 3 Seoul National University Hospital, Seoul/KR
  • 4 Janssen R&D, Spring House/US
  • 5 Janssen Global Commercial Strategy Organization RWE, Raritan/US
  • 6 Janssen R&D, 08869 - Spring House/US
  • 7 New York University Langone Health, New York/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 19P


The recommended frontline therapy for patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC is osimertinib (osi), a 3rd‐generation (gen) EGFR tyrosine kinase inhibitor (TKI); however, most will develop resistance. Approximately 28% of frontline pts treated with a 1st/2nd-gen EGFR TKI die before receiving a 2nd line of therapy (LOT) (Nieva Drugs Real World Outcomes 2022; 9:333–345). This analysis estimated mortality in EGFRm NSCLC after starting frontline osi and before 2nd LOT to determine if there is an improvement to historical rates.


Data from the ConcertAI (Cambridge, MA) Patient360 NSCLC database (>100 geographically dispersed community US oncology practices) were analyzed descriptively. Included pts were diagnosed with advanced NSCLC between 1 Jan 2018 and 16 Aug 2022, had confirmed EGFR exon 19 deletions (ex19del) or exon 21 L858R mutations, and received osi (primary analysis) or 1st/2nd-gen EGFR TKI (ie, afatinib, erlotinib, or gefitinib) as frontline monotherapy.


In the ConcertAI Patient360 database, 1,135 pts had confirmed EGFR ex19del or L858R; of which 467 (41%) received osi as frontline monotherapy. Among this frontline osi population, 119 (25%) died before receiving a subsequent LOT. Documented start of a 2nd LOT was observed in 133 (28%) of frontline osi-treated pts. The remaining 215 (46%) did not have documented start of a 2nd LOT, which could be due to ongoing frontline use. A similar proportion of frontline 1st/2nd-gen EGFR TKI pts died prior to a 2nd LOT (20%; table). Survival outcomes will be presented at the meeting. These results are also being evaluated in a 2nd dataset, which may be available at time of presentation.

Table: 19P

Patient attrition

Of patients receiving frontline, n (%)Osimertinib (n = 467)1st or 2nd-gen EGFR TKI (n = 61)a
Median follow-up2.1 years2.9 years
Died during frontline119 (25)12 (20)
No documented start of 2nd LOT215 (46)8 (13)
Started 2nd LOT133 (28)41 (67)

Cross-cohort analysis was not conducted, and therefore, confounding factors cannot be ruled out.


The proportion of EGFRm NSCLC pts dying while on frontline osi (25%) remains high, demonstrating many never get to a 2nd LOT. Further optimization of frontline therapy is needed to improve patient outcomes.

Editorial acknowledgement

Medical writing support was provided by Lumanity Communications, Inc.

Legal entity responsible for the study

The authors.




N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer Ingelheim, Novartis, Sanofi, AbbVie, Amgen, Eli Lilly, Grunenthal, Takeda, Owkin; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS; Non-Financial Interests, Personal, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Personal, Other, Family member is an employee: AstraZeneca. N. Leighl: Financial Interests, Personal, Other, CME/independent lectures: MSD, BMS, Hoffmann LaRoche, EMD Serono; Financial Interests, Personal, Invited Speaker, independent lectures: Novartis, Takeda; Financial Interests, Personal, Advisory Board: Puma Biotechnology; Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, Array, Bayer, EMD Serono, Guardant Health, Eli Lilly, MSD, Pfizer, Roche, Takeda. Y. Ohe: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, ONO, BMS, Eli Lilly, Boehringer Ingelheim, Takeda, MSD, Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Celltrion, Amgen, Nippon Kayaku, Takeda, Pfizer, ONO, Janssen, AnHeart Therapeutics Inc; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Eli Lilly, Janssen, Amgen; Financial Interests, Personal and Institutional, Invited Speaker: Takeda, ONO; Non-Financial Interests, Personal, Leadership Role: JSMO, JLCS, JCOG; Non-Financial Interests, Personal, Member: ASCO. T.M. Kim: Financial Interests, Personal, Advisory Role: Honoraria for lectures from AstraZeneca, IMBDx, Inc., Takeda, and Yuhan; Financial Interests, Personal, Other: AstraZeneca, Janssen, Regeneron, Samsung. L. Demirdjian: Financial Interests, Personal, Full or part-time Employment: Janssen. A.B. Bourla: Financial Interests, Personal, Full or part-time Employment: Flatiron Health/ Roche Group, Janssen R & D. A. Abdul Sultan: Financial Interests, Personal, Full or part-time Employment: Janssen. P. Mahadevia: Financial Interests, Personal, Full or part-time Employment: Janssen; Financial Interests, Personal, Stocks/Shares: Johnson & Johnson. J.M. Bauml: Financial Interests, Personal, Full or part-time Employment: Janssen; Financial Interests, Personal, Stocks/Shares: Johnson & Johnson. J. Sabari: Financial Interests, Personal, Advisory Board: AstraZeneca, Genentech, Janssen, Pfizer, Regeneron, Sanofi Genzyme, Takeda, Mirati Therapeutics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.